Back to search results

SCIPI Program for Localized Prostate Cancer

This study is testing a web-based program called SCIPI (Support, Communication, and Information Program for Prostate Cancer - Interactive) for people with localized prostate cancer. SCIPI offers educational materials, skills training, and interactive tools through your MyChart system to help you make informed treatment decisions. The study wants to see if SCIPI can be easily used in prostate cancer care and if it helps improve your confidence in choosing treatments and your overall quality of life. You may be able to join if you are 18 or older, have a new diagnosis of localized prostate cancer, are eligible for curative treatment, and can read English or Spanish. The study is currently unclear on its recruitment status and aims to enroll 200 participants. Success will be measured by how satisfied participants are with their treatment decisions at 3 and 6 months.

Study design
This is a pilot study that will randomly assign 200 newly diagnosed patients to either receive the SCIPI program or usual care. Family members can also participate.
What's involved
You will complete a baseline assessment, and then data will be collected at 3 months and 6 months after starting the study.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07280897

SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial

Not Yet Recruiting
NAAges 18+InterventionalSupportive care
The University of Texas Health Science Center at San Antonio
~200 participants
Updated 2025-12-19 on ClinicalTrials.gov
What's tested:SCIPI

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Satisfaction with Decision (SWD)
Measured over 3-month follow-up (T2) and 6-month follow-up (T3)

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Lixin Song, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio

Who to contact

Lixin Song, PhD
[email protected]
210-450-8561
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years.
Biopsy-confirmed diagnosis of localized prostate cancer (Gleason score ≤8, PSA \< 30 ng/mL).
Eligible for curative-intent treatment (e.g., surgery, radiation, or active surveillance).
Able to read and understand English or Spanish.
Access to the internet and the Epic MyChart patient portal at a participating study site (UTHSA, UNC, UCSD, or KUMC).
Willing and able to provide informed consent.

Exclusion

History of metastatic or recurrent prostate cancer.
Diagnosis of another active malignancy (excluding non-melanoma skin cancer).
Severe cognitive impairment or psychiatric illness that would interfere with participation.
Inability to access the internet or the MyChart portal.
Prior participation in other related digital health trials.

What this trial measures

  • Satisfaction with Decision (SWD)3-month follow-up (T2) and 6-month follow-up (T3)

    SWD will be assessed using the 6-item Satisfaction with Decision (SWD) scale, which measures the extent to which participants feel informed, confident, and satisfied with their prostate cancer treatment decision. Scores range from 6 to 30, with higher scores indicating greater satisfaction.